(NASDAQ: AMRX) Amneal Pharmaceuticals's forecast annual revenue growth rate of 11.48% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 3,693.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,573.61%.
Amneal Pharmaceuticals's revenue in 2026 is $2,934,959,000.On average, 6 Wall Street analysts forecast AMRX's revenue for 2026 to be $1,028,595,474,240, with the lowest AMRX revenue forecast at $981,126,673,320, and the highest AMRX revenue forecast at $1,065,690,298,800.
In 2027, AMRX is forecast to generate $1,112,530,373,880 in revenue, with the lowest revenue forecast at $1,051,229,604,480 and the highest revenue forecast at $1,156,226,819,760.